- Home
- RSF vs JNJ Comparison
RSF vs JNJ Comparison
Compare RSF & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- JNJ
- Stock Information
- Founded
- RSF 2016
- JNJ 1886
- Country
- RSF United States
- JNJ United States
- Employees
- RSF N/A
- JNJ N/A
- Industry
- RSF Investment Managers
- JNJ Biotechnology: Pharmaceutical Preparations
- Sector
- RSF Finance
- JNJ Health Care
- Exchange
- RSF Nasdaq
- JNJ Nasdaq
- Market Cap
- RSF 49.1M
- JNJ 373.9B
- IPO Year
- RSF N/A
- JNJ 1944
- Fundamental
- Price
- RSF $14.54
- JNJ $155.55
- Analyst Decision
- RSF
- JNJ Buy
- Analyst Count
- RSF 0
- JNJ 16
- Target Price
- RSF N/A
- JNJ $169.33
- AVG Volume (30 Days)
- RSF 11.8K
- JNJ 7.9M
- Earning Date
- RSF 01-01-0001
- JNJ 07-16-2025
- Dividend Yield
- RSF 10.61%
- JNJ 3.34%
- EPS Growth
- RSF N/A
- JNJ N/A
- EPS
- RSF N/A
- JNJ 8.98
- Revenue
- RSF N/A
- JNJ $89,331,000,000.00
- Revenue This Year
- RSF N/A
- JNJ $3.87
- Revenue Next Year
- RSF N/A
- JNJ $4.14
- P/E Ratio
- RSF N/A
- JNJ $17.31
- Revenue Growth
- RSF N/A
- JNJ 4.30
- 52 Week Low
- RSF $14.81
- JNJ $140.68
- 52 Week High
- RSF $16.23
- JNJ $169.99
- Technical
- Relative Strength Index (RSI)
- RSF 32.63
- JNJ 56.58
- Support Level
- RSF $14.58
- JNJ $151.01
- Resistance Level
- RSF $14.73
- JNJ $157.75
- Average True Range (ATR)
- RSF 0.09
- JNJ 2.15
- MACD
- RSF -0.00
- JNJ 0.27
- Stochastic Oscillator
- RSF 3.85
- JNJ 74.74
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.